A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Nanjing Leads Biolabs Co.,Ltd
Revolution Medicines, Inc.
Inhibrx Biosciences, Inc
Bristol-Myers Squibb
Columbia University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cantargia AB
Altor BioScience
University of Regensburg
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
Merck Sharp & Dohme LLC
Swedish Orphan Biovitrum
Eisai Inc.
Altor BioScience
University Health Network, Toronto
Rabin Medical Center